On the heels of a $6.9B As­traZeneca pact, IP dis­pute be­tween Dai­ichi Sankyo and Seat­tle Ge­net­ics rips open in law­suit

A long-run­ning col­lab­o­ra­tion on ADC tech with Seat­tle Ge­net­ics that end­ed 4 years ago has come back to haunt Dai­ichi Sankyo.

Sev­en months af­ter As­traZeneca stepped up with a record-set­ting $6.9 bil­lion deal to li­cense a high­ly promis­ing can­cer drug that ap­pears poised for a near-term ap­proval, Dai­ichi Sankyo has called up the le­gal troops to fight back in court against Seat­tle Ge­net­ics’ claim to their IP, stem­ming from their tech al­liance.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER